UNSPSC 51101699: Pentamidine isethionate

This classification denotes an antiprotozoal agent and antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V2P3K60DA2. European Medicines Agency schedules Pentamidine diisetionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12202MIG. Pentamidine isethionate generally arises in the molecular formula C19H24N4O2.2C2H6O4S. The term 'pentamidine isethionate' is a European Pharmacopoeia designation. Most nations schedule pentamidine isethionate under HS 29252900 and SITC 51482.

As of Q4 2014, PENTAMIDINE ISETHIONATE remains the US FDA Preferred Term for this commodity. Pentamidine isethionate bears US NLM identifiers UMLS ID C0591959 and NCI Concept Code C29349. SMILES: C1CC(CCC1C(=N)N)OCCCCCOC2CCC(CC2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O.

UNSPSC 51101699 Pentamidine isethionate is a Commodity code for a specific pharmaceutical product, but recent state and local solicitations tagged under this code show limited direct relevance to pentamidine itself. The most recent posted opportunity record—a completed piggyback pharmaceutical warehouse award by the Illinois Department of Public Health to Chartwell Rx LLC on August 28, 2026—involved Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets, not pentamidine. A second record, a Seminole County, Florida IFB for Naloxone and Safe Drug Deactivation Systems, is similarly unrelated to the code's nominal scope. The mismatch suggests that either the tagging in these opportunities is imprecise or the code sees minimal recent activity directly aligned with pentamidine procurement.

State and local governments purchasing under this code appear to include state departments of public health and county health authorities. Geographic activity in recent records centers on Illinois and Florida, though the sample is too small to characterize broader regional distribution. Buyers use cooperative purchasing vehicles such as MMCAP Infuse consortium piggyback contracts alongside direct IFB processes. Opportunities are typically annual or multi-year supply agreements with renewal options and quarterly or as-needed deliveries. Without recent solicitations specifically targeting pentamidine isethionate, assess whether the code's actual procurement volume and issuing-body frequency support pursuit; the tagged opportunities suggest either minimal current activity or taxonomy misalignment in state and local procurement systems.